Though only three-years old, the small Swiss biotech, Asceneuron, has raised $30.6 million to help fund studies for a new candidate drug for Alzheimer’s disease (AD). Asceneuron’s focus is on small-molecule drug discovery for tauopathies and neurodegenerative disease, such as AD and frontotemporal dementia (FTD). The drug currently at the forefront of their repertoire is ASN-561, an inhibitor of O-GlcNAase (OGA), which, based on preclinical data, can decrease amyloid plaque formation and cognitive decline in a transgenic mouse model of AD. ASN-561 is also under development by the company as a candidate therapy for FTD.
Click here to read more.